Cancer Stem Cell News Volume 12.45 | Dec 6 2023

    0
    131








    2023-12-06 | CSCN 12.45


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 12.45 – 6 December, 2023
    TOP STORY

    SPINK1-Induced Tumor Plasticity Provides a Therapeutic Window for Chemotherapy in Hepatocellular Carcinoma

    Investigators showed SPINK1 to strongly associate with CD133 + hepatocellular carcinoma and tumor dedifferentiation.
    [Nature Communications]

    Full Article
    Discover new celli Isolation technologies
    PUBLICATIONSRanked by the impact factor of the journal

    An Ellagic Acid Coordinated Copper-Based Nanoplatform for Efficiently Overcoming Cancer Chemoresistance by Cuproptosis and Synergistic Inhibition of Cancer Cell Stemness

    Ellagic acid inhibited stemness maintenance by suppressing the hedgehog pathway, while Cu2+ further decreased stemness features of tumor cells by disrupting mitochondrial metabolism, effectively enhancing doxorubicin-mediated chemotherapy.
    [Small]

    Abstract

    Targeting ABCA12-Controlled Ceramide Homeostasis Inhibits Breast Cancer Stem Cell Function and Chemoresistance

    Scientists developed a stem cell factor SOX9-based reporter for isolating CSCs in primary tumors and metastases of spontaneous mammary tumor models.
    [Science Advances]

    Full Article

    RAB27B-Regulated Exosomes Mediate LSC Maintenance via Resistance to Senescence and Crosstalk with the Microenvironment

    Investigators found that increased RAB27B in leukemia stem cells prevented their senescence and maintained their stemness in vitro and in vivo.
    [Leukemia]

    Abstract

    MiR-204 Suppresses Cancer Stemness and Enhances Osimertinib Sensitivity in Non-Small Cell Lung Cancer by Targeting CD44

    Scientists explored novel miRNA–mRNA regulatory mechanisms that contribute to osimertinib resistance in lung cancer. They found that miR-204 expression in osimertinib-resistant lung cancer cells was markedly reduced compared to that in osimertinib-sensitive parental cells.
    [Molecular Therapy – Nucleic Acids]

    AbstractFull ArticleGraphical Abstract

    SIX1 Amplification Modulates Stemness and Tumorigenesis in Breast Cancer

    Researchers demonstrated that the expression of sine oculis homeobox homolog 1 (SIX1) varied among different subtypes of breast cancer and that it upregulated breast cancer grading and lymph node metastasis.
    [Journal of Translational Medicine]

    Full Article

    METTL3 Facilitates Stemness Properties and Tumorigenicity of Cancer Stem Cells in Hepatocellular Carcinoma through the SOCS3/JAK2/STAT3 Signaling Pathway

    Loss- and gain-of-function experiments were utilized to assess the biological effects of METTL3 and SOCS3 on the proliferation and stemness phenotypes in vitro and in vivo.
    [Cancer Gene Therapy]

    Abstract

    Periostin Facilitates Ovarian Cancer Recurrence by Enhancing Cancer Stemness

    Scientists examined how elevated extracellular periostin, as they found was present in recurrent ovarian cancer (OC), impacted OC cell functions and phenotypes, including stemness.
    [Scientific Reports]

    Full Article

    Distinctive Mesenchymal-Like Neurofibroma Stem Cells Shape NF1 Clinical Phenotypes Controlled by BDNF Microenvironment

    Researchers determined the phenotypic and therapeutic relevance of tumor microenvironment in neurofibroma type I (NF1) patients. Tumor stem cells from NF1 were isolated and cultured using fluorescence-activated cell sorting and colony formation experiments.
    [Translational Oncology]

    Abstract
    Learn strategies and tips for choosing which scientific conferences to attend.
    REVIEWS

    Cancer Stem Cells and Their Niche in Cancer Progression and Therapy

    The authors highlight the factors within the CSC niche that have important roles in regulating CSC properties, including the extracellular matrix, stromal cells, cancer-associated fibroblasts, mesenchymal stem cells, and physiological changes.
    [Cancer Cell International]

    Full Article
    INDUSTRY AND POLICY NEWS

    AbbVie Buys Immunogen, Maker of Targeted Cancer Drugs, for $10 Billion

    AbbVie announced that the company will pay $10 billion to the biotech firm Immunogen for the acquirement of an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.
    [STAT]

    Press Release
    FEATURED EVENT

    6th DNA Repair/Replication Structures and Cancer Conference

    February 14 – 18, 2024
    Cancun, Mexico

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Cancer Biology

    Albert Einstein College of Medicine – Bronx, New York, United States

    Postdoctoral Researcher – Gliomas

    Jinfeng Labs & Institute of Functional Genomics – Chongqing, China

    Faculty Positions – Medicine

    Westlake University – Zhejiang, China

    Assistant Professor Position – 3D Tissue Organoids

    Swammerdam Institute for Life Sciences – Amsterdam, Netherlands

    Research Assistant – Epigenetics

    Babraham Institute – Cambridge, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2